A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects wiht moderate to severe chronic plaque-type psoriasis on eiher a fixed dose regimen or on a retreatment at start of relapse regimen Sculpture